Shore Capital Reaffirms Buy Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating reissued by equities research analysts at Shore Capital in a report released on Wednesday, MarketBeat.com reports.

Several other equities research analysts have also commented on GSK. Barclays restated an “equal weight” rating and issued a GBX 1,725 ($21.67) price objective on shares of GSK in a research report on Monday, April 8th. Berenberg Bank upped their price objective on GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 ($24.49) price objective on shares of GSK in a research report on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, GSK currently has a consensus rating of “Hold” and a consensus target price of GBX 1,675.63 ($21.05).

GSK Price Performance

Shares of LON GSK opened at GBX 1,728.50 ($21.71) on Wednesday. The business’s 50 day moving average price is GBX 1,662.06 and its 200 day moving average price is GBX 1,556.29. The firm has a market cap of £70.70 billion, a P/E ratio of 1,440.42, a P/E/G ratio of 1.12 and a beta of 0.27. GSK has a 52 week low of GBX 1,302.60 ($16.36) and a 52 week high of GBX 1,729.50 ($21.72). The company has a quick ratio of 0.73, a current ratio of 0.88 and a debt-to-equity ratio of 140.82.

Insider Transactions at GSK

In other news, insider Emma Walmsley sold 139,792 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of GBX 1,658 ($20.83), for a total transaction of £2,317,751.36 ($2,911,382.19). In other GSK news, insider Urs Rohner bought 434 shares of GSK stock in a transaction dated Wednesday, March 20th. The stock was acquired at an average cost of GBX 1,662 ($20.88) per share, with a total value of £7,213.08 ($9,060.52). Also, insider Emma Walmsley sold 139,792 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of GBX 1,658 ($20.83), for a total value of £2,317,751.36 ($2,911,382.19). Corporate insiders own 1.77% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.